Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „RoActemra · 4.8 · RA patients“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.8 · 15 Description of selected adverse reactions RA patients Infections In the 6-month controlled trials the rate
Eintrag öffnenRoActemra · 4.8 · 16 DMARDs. Approximately half of the patients who developed an ANC < 1 × 109/ L did so within 8 weeks after st
Eintrag öffnenRoActemra · 4.8 · 17 COVID-19 patients Infections In the pooled safety-evaluable population from Trials ML42528, WA42380, and WA
Eintrag öffnenRoActemra · 4.8 · 19 Immunogenicity All 112 patients were tested for anti-tocilizumab antibodies at baseline. Two patients devel
Eintrag öffnenRoActemra · 4.8 · 46 Table 1. List of adverse reactions occurring in patients treated with tocilizumab
Eintrag öffnenRoActemra · 4.8 · 49 Injection Site Reactions A total of 28.8 % (15/52) pJIA patients experienced ISRs to tocilizumab subcutaneo
Eintrag öffnenRoActemra · 4.8 · 81 Table 1. List of adverse reactions occurring in patients treated with tocilizumab
Eintrag öffnenRoActemra · 4.8 · 84 Lipid parameters In the 52-week open-label subcutaneous trial (WA28118), 23.4 % and 35.4 % of patients expe
Eintrag öffnenRoActemra · 4.8 · 85 Injection site reactions In the tocilizumab subcutaneous weekly group, a total of 6 % (6/100) patients repo
Eintrag öffnenRoActemra · 4.8 · CRS patients The safety of tocilizumab in CRS has been evaluated in a retrospective analysis of data from clin
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (intravenous use) RA patients The safety of tocilizumab has been stu
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (intravenous use) RA patients The safety of tocilizumab has been stu
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (subcutaneous use) RA patients The safety of subcutaneous tocilizuma
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (subcutaneous use) RA patients The safety of subcutaneous tocilizuma
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions in sJIA patients The safety profile of intravenous tocilizumab in sJ
Eintrag öffnenRoActemra · 4.8 · GCA patients The safety of subcutaneous tocilizumab has been studied in one Phase III trial (WA28119) with 251
Eintrag öffnenRoActemra · 4.8 · GCA patients The safety of subcutaneous tocilizumab has been studied in one Phase III trial (WA28119) with 251
Eintrag öffnenRoActemra · 4.8 · Hepatobiliary disorders Hepatic transaminases increased 1 Patients are counted once for each category regardle
Eintrag öffnenRoActemra · 4.8 · Immunogenicity A total of 2 876 patients have been tested for anti-tocilizumab antibodies in the 6-month contr
Eintrag öffnenRoActemra · 4.8 · Immunogenicity A total of 2 876 patients have been tested for anti-tocilizumab antibodies in the 6-month contr
Eintrag öffnen